Clinical Impact: Guidelines, Consensus Statements and Policy

Clinical Care Guidelines

  • NIHR Global Research Health Unit on Global Surgery, Glasbey JC, Moore R, Ademuyiwa A, Adisa A, Biccard B, Chakrabortee S, Ghosh D, Harrison E, Jones C, Lapitan MC, Lawani I, Maimbo M, Martin J, Maxwell A, Morton D, Ntirenganya F, Nepogodiev D, Pinkney T, Ramos-De la Medina A, Qureshi AU, Simoes J, Tabiri S, Bhangu A, et al. Global guidelines for emergency general surgery: systematic review and Delphi prioritization process. BMJ Open 2022;6(1):zrac005 doi: 10.1093/bjsopen/zrac005
  • WFSA Coronavirus - guidance for anaesthesia and perioperative care providers. Feb 19, 2020. https://www.wfsahq.org/resources/coronavirus
  • Martin J, Kumara T, Shalabi H, Keita N, Sherman LM, Cheng D, Cherian M. World Health Organization guidance for the surgical care of patients during an Ebola outbreak. Evidence-informed decision making for the management of patients with surgical conditions in the context of Ebola Virus Disease. 2020 Submitted. 
  • National Institute for Health Research Global Research Health Unit on Global Surgery. Delphi prioritization and development of global surgery guidelines for the prevention of surgical site infection. Br J Surg. 2020;107(8):970-977. Epub 2020 Mar 24. https://doi.org/10.1002/bjs.11530
  • WHO Guidelines Panel. Global guidelines for the prevention of surgical site infection; 2018 update to the High versus Low Fi02 Oxygen Supplementation. World Health Organization: Geneva; 2018. 
  • Kuijpers T, Spencer FA, Siemieniuk RA, Vandvik PO, Otto CM, Lytvyn L, Mir H, Jin AY, Manja V, Karthikeyan G, Hoendermis E, Martin J, Carballo S, O’Donnell M, Vartdal T, Baxter C, Patrick-Lake B, Scott J, Agoritsas T, Guyatt G. Rapid recommendations: Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ 2018;362:k2515. doi: https://doi.org/10.1136/bmj.k2515
  • Choosing Wisely Canada, Critical Care Campaign Task Force. Critical Care: Five things clinicians and patients should question (Practice Guidelines) 2017 March 22.
  • Drugs That May Cause or Exacerbate Heart Failure, A Scientific Statement from the American Heart Association. Page RL 2nd, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J; On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure, A Scientific Statement from the American Heart Association. Circulation. 2016 Aug 9;134(6): e32-69
  • Nicolaou G, Ismail M, Cheng D. Thoracic endovascular aortic repair: update on indications and guidelines. Anesthesiology Clinics of North America. ed. Koch C. 2013; 31(2):451-478.  
    DOI:https://doi.org/10.1016/j.anclin.2013.01.001
  • Greenspoon J, Barkun A, Bardou M, Chiba N, Leontiadis GI, Marshall JK, Metz DC, Romagnuolo J, Sun J; International Consensus Upper Gastrointestinal Bleeding Conference Group (Hunt R, Barkun AN, Bardou M, Kuipers EJ, Sung J, Agreus L, Armstrong D, Calvet X, Chiba N, Cipolletta L, Cohen H, Enns R, Ericsson LG, Gralnek I, Jensen D, Kaminishi M, Kanwal F, Laine L, Lanas A, Lau J, Leontiadis G, Lundell L, Malfertheiner P, Marshall J, Martin J, Metz D, Moayyedi P, Quenot JP, Rauws E, Romagnuolo J, Rostom A, Spiegel B, Tse F, Van Leerdam M, Van Rensburg C). Management of patients with nonvariceal upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2012;10(3):234-9. https://doi.org/10.1016/j.cgh.2011.07.025

Consensus Conferences & Statements

  • Marcus HJ, Bennett A, Chari A, Day T, Hirst A, Hughes-Hallett A, Kolias A, Kwasnicki RM, Martin J, Rovers M, Squire SE, McCulloch P. IDEAL-D Framework for Device Innovation: A Consensus Statement on the Preclinical Stage. Ann Surg 2022; 275(1):73-79. doi: 10.1097/SLA.0000000000004907. Online ahead of print.
  • Davies JI, Gelb AW, Gore-Booth J, Martin J (Utstein Global Surgery Indicators Writing Group); Mellin-Olsen J, Åkerman C, Ameh EA, Biccard BM, Braut GS, Chu K, Derbew M, Ersdal, HL, Guzman JM, Hagander L, Haylock-Loor, C, Holmer H, Johnson, W, Juran S, Kassebaum, NJ, Laerdal T, Leather AJ, Lipnick MS, Ljungman D, Makasa EMM, Meara JG, Newton, M.W, Østergaard D, Reynolds T, Romanzi LJ, Santhirapala V, Shrime, M.G.; Søreide K, Steinholt M, Suzuki E, Varallo, JE, Visser GH, Watters D, Weiser TG. Global Surgery, Obstetric, and Anesthesia Indicator Definitions and Reporting: An Utstein Consensus Report. PLOS Med 2021. 2021 Aug 20;18(8):e1003749. doi: 10.1371/journal.pmed.1003749. eCollection 2021 Aug.
  • Bilbro N, Hirst A, Paez A, Vasey V, Pfulete M, Sedrakyan A, McCulloch P, on behalf of the IDEAL Collaboration Reporting Guidelines Working Group. The IDEAL Reporting Guidelines: A delphi consensus statement stage specific recommendations for reporting the evaluation of surgical innovation. Ann Surg 2021;273(1):82-85. Doi: 10.1097/SLA.0000000000004180
  • Ariyan S, Martin J, Lal A, Cheng D, Borah GL, et al. Antibiotic prophylaxis for preventing surgical-site infection in plastic surgery: an evidence-based consensus conference statement from the American Association of Plastic Surgeons. Plast Reconstr Surg. 2015 Jun;135(6):1723-39. doi: 10.1097/PRS.0000000000001265
  • Puskas JD, Martin J, Cheng D, Benussi S, Bonatti JO, et al. ISMICS Consensus Conference and Statements of Randomized Controlled Trials of Off-Pump Versus Conventional Coronary Artery Bypass Surgery. Innovations (Phila). 2015;10(4):219-29. https://doi.org/10.1097/imi.0000000000000184
  • Turina MI, Shennib H, Dunning J, Cheng D, Martin J, Muneretto C, Schueler S, von Segesser L, Sergeant PT; EACTS/ESCVS committee. EACTS/ESCVS best practice guidelines for reporting treatment results in the thoracic aorta. Eur J Cardiothorac Surg. 2009 Jun;35(6):927-30. PMID: 19339194. DOI: 10.1016/j.ejcts.2008.10.056
  • Falk V, Cheng D, Martin J, Diegeler A, Folliguet T, et al. Minimally invasive versus conventional open mitral valve surgery: A consensus statement of the International Society of Minimally Invasive Coronary Surgery (ISMICS) 2010. Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery 2011;6(2):66-76. https://doi.org/10.1097/imi.0b013e318216be5c
  • Menkis A, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, et al. Drugs, Devices, Technologies & Techniques for Blood Management in Minimally-Invasive and Conventional Cardiothoracic Surgery: A Consensus Statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery 2012;7(4):229-241. https://doi.org/10.1097/imi.0b013e3182747699
  • Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; International Consensus Upper Gastrointestinal Bleeding Conference Group (Hunt R, Barkun AN, Bardou M, Kuipers EJ, Sung J, Agreus L, Armstrong D, Calvet X, Chiba N, Cipolletta L, Cohen H, Enns R, Ericsson LG, Gralnek I, Jensen D, Kaminishi M, Kanwal F, Laine L, Lanas A, Lau J, Leontiadis G, Lundell L, Malfertheiner P, Marshall J, Martin J, Metz D, Moayyedi P, Quenot JP, Rauws E, Romagnuolo J, Rostom A, Spiegel B, Tse F, Van Leerdam M, Van Rensburg C, Jones DJ, Gardeazabal A, Rácz I, Lavigne P, Sinclair P). International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101-13. https://doi.org/10.7326/0003-4819-152-2-201001190-00009
  • Ad N, Cheng D, Martin J, Berglin E, Chang BC, et al. Surgical ablation for atrial fibrillation in cardiac surgery: a consensus statement of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) 2009. Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery 2010;5(2):74-83. https://doi.org/10.1097/imi.0b013e3181d72939

Reports & Policy Support

  • Lund H, Juhl C, Borgaard B, Draborg E, Henriksen M, Andreasen J, Christensen R, Nasser M, Ciliska D, Tugwell P, Clarke M, Blaine C, Martin J, Ban JW, Brunnhuber K, Robinson K. Using an evidence-based research approach to place your results into context after the study is performed to ensure usefulness of the conclusion. J Clin Epi 2021; 129:167-171. https://doi.org/10.1016/j.jclinepi.2020.07.021
  • Lund H, Juhl CB, Norgaard B, Draborg E, Henriksen M, Andreasen J, Christensen R, Nasser M, Ciliska D, Clarke M, Tugwell P, Martin J, Blaine C, Brunnhuber K, Robinson KA, on behalf of the Evidence-Based Research Network. Using an evidence-based research approach before a new study is conducted to ensure value. J Clin Epi 2021; 129: 158-166. doi: https://doi.org/10.1016/j.jclinepi.2020.07.019
  • Odland ML, Nepogodiev D, Morton D, Martin J, Bekele A, Davis J, Weiser T. Identifying a basket of surgical procedures to standardize global surgical metrics: an international Delphi study. Ann Surg 2021; 274(6):1107-1114. doi:10.1097/SLA.0000000000004611
  • Tugwell P , Welch VA, Karunananthan S, Maxwell LJ, Akl EA, Avey MT, Bhutta ZA, Brouwers MC , Clark JP, Cook S, Cuervo LG, Curran JA, Ghogomu ET , Graham IG, JGrimshaw JM, Hutton B, Ioannidis JPA, Jordan Z, Jull JE, Kristjansson E, Langlois EV, Little J, Anne Lyddiatt, Martin J, Marušić A, Mbuagbaw L , Moher D, Morton RL, Nasser M, Page M, Pardo JP, Petkovic J, Petticrew M, Piggott T, Pottie K, Rada G, Rader T, Riddle AY, Rothstein H, Schunemann H, Shamseer L, Shea BJ, Simeon R, Siontis KC, Maureen Smith M, Soares-Weiser K, Thavorn K, Tovey D, Vachon B, Valentine J, Villemaire R, Peter Walker , Weeks L, Wells G, Wilson D, White H. When and when not to replicate systematic reviews of interventions: consensus checklist. BMJ 2020;370;m2864 doi: https://doi.org/10.1136/bmj.m2864
  • Recommendation Framework for Ontario Drug Decisions: Advice for the Ontario MOHLTC Committee to Evaluate Drugs, 2018.
  • Deliberative Framework for Ontario Public Drug Decisions: Recommendations for the Ontario MOHLTC Committee to Evaluate Drugs, 2018.
  • Martin J, Invited Contributor to: “Unleashing Innovation: Excellent Healthcare for Canada. Report of the Advisory Panel on Healthcare Innovation”, submitted to the Honourable Rona Ambrose, Minister of Health, Government of Canada, 2015. MEDICI's Role: To contribute to the chapter on healthcare innovation.
  • Polisena J, Lavis J, Graham I, Harstall C, Juzwishin D, Veysey-McLean P, Martin J. Supporting the use of health technology assessments in decision makers. Healthcare Policy. 2015 May;10(4):10-15. PMID: 26142355. doi:10.12927/hcpol.2015.24208
  • HTA Exchange. Ethical, Legal, Social & Implementation Issues in Health Technology Assessment. Report of the HTA Exchange National Retreat to the Canadian Agency for Drugs and Technologies in Health, Nov 2014. MEDICI's Role: To Chair the national retreat, and to oversee the engagement with HTA methodologists and decision-makers, and contribute to writing and circulating the report for feedback.
  • Clarke JTR, Coyle D, Evans G, Martin J, Winquist E. Toward a functional definition of ‘rare disease’ for regulatory agencies and funding agencies. Value in Health. 2014;17(8):757-61. PMID: 25498770.  https://doi.org/10.1016/j.jval.2014.08.2672
  • Government of Canada White Paper. Health Technology Assessment, Health Technology Management and Decision-Making in Canada: Combining Evidence, Economics, and Contextualized Social-Legal-Ethical-Implementation Issues to Improve Healthcare in Care, Jan 2012. White paper invited by Health Canada to explore Know4Go as an innovative framework to link the evidence, economics, ethics (and other essential ‘sleeper’ aspects that influence decision-making), in order to make explicit the multidimensional opportunity cost “tradeoffs” when assessing multiple technologies at various levels of decision-informing (national planning, government and regional decision-making and implementation). The potential for using the framework to visualize the dependent links and tradeoffs between technology uptake and disinvestment was proposed from a variety of perspectives as a basis to increase national coordination of health technology assessment and management, while respecting the need to maintain independence and contextualization at the provincial level. Linking planning, assessment, implementation, with real-world outcomes feedback into the framework was emphasized.
  • Winquist E, Coyle D, Evans G, Clark J, Chan W, Sabharwal M, Martin J. Policy Framework for Drugs for Rare Diseases, Ontario Framework for Drugs for Rare Diseases (DRDs), co-developer of policy for drugs for rare diseases. This policy framework was developed to guide Ontario policy decisions related to drugs for rare and ultra-orphan diseases. In 2011-2013, given the progression toward a national approach to rare disease formulary decisions in Canada, this policy framework was used to inform the design of the national framework for rare disease drug funding. MEDICI's Role: Dr. Janet Martin co-developed the original framework by contributing to developing the policy question, performing underlying research, synthesizing evidence, and trialing the framework iteratively to real-world requests for drugs for rare diseases at the Ontario Ministry of Health, oversaw the process and manuscript as senior author.
  • Jones DJ, Barkun AN, Lu Y, Enns R, Sinclair P, Martel M, Gralnek I, Bardou M, Kuipers EJ, Sung J; International Consensus Upper Gastrointestinal Bleeding Conference Group (Agreus L, Armstrong D, Calvet X, Chiba N, Cipolletta L, Cohen H, Ericsson LG, Hunt R, Jensen D, Kaminishi M, Kanwal F, Laine L, Lanas A, Lau J, Leontiadis G, Lundell L, Malfertheiner P, Marshall J, Martin J, Metz D, Moayyedi P, Quenot JP, Rauws E, Romagnuolo J, Rostom A, Spiegel B, Tse F, Van Leerdam M, Van Rensburg C). Conflicts of interest ethics: silencing expertise in the development of international clinical practice guidelines. Ann Intern Med. 2012;156(11):809-16, W-283. PMID: 22665816. https://doi.org/10.7326/0003-4819-156-11-201206050-00008
  • Winquist E, Bell CM, Clarke JT, Evans G, Martin J, Sabharwal M, Gadhok A, Stevenson H, Coyle D. An evaluation framework for funding drugs for rare diseases. Value Health. 2012;15(6):982-6. PMID: 22999151. https://doi.org/10.1016/j.jval.2012.06.009
  • Approximately 30 policy advice reports (confidential) to the Committee to Evaluate Drugs and the Executive Officer of the Minister of Health, Ontario Ministry of Health and Long Term Care, 2010-present